Efficacy and Safety of Oral Anticoagulants in Patients with Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease.

[1]  Hugh Calkins,et al.  Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Circulation.

[2]  Y. Kao Yang,et al.  The Chang Gung Research Database—A multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan , 2019, Pharmacoepidemiology and drug safety.

[3]  P. Noseworthy,et al.  Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States , 2018, Circulation.

[4]  S. Manzano-Fernández,et al.  Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation , 2018, European journal of clinical investigation.

[5]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[6]  Shou-Hsia Cheng,et al.  Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study , 2018, Scientific Reports.

[7]  K. Jurk,et al.  Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations , 2017, International journal of nephrology and renovascular disease.

[8]  J. Olesen,et al.  Effect of Reduced Renal Function on Time in Therapeutic Range Among Anticoagulated Atrial Fibrillation Patients. , 2017, Journal of the American College of Cardiology.

[9]  J. Segal,et al.  Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease , 2017, Journal of Nephrology.

[10]  E. Black-Maier,et al.  Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? , 2017, Heart.

[11]  M. Turakhia,et al.  Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease , 2016, Heart.

[12]  J. Olesen,et al.  Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study , 2016, Stroke.

[13]  J. Segal,et al.  Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis , 2016, BMC Nephrology.

[14]  P. Ravani,et al.  Atrial fibrillation and chronic kidney disease: struggling through thick and thin. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  G. Lip,et al.  Atrial Fibrillation and Thromboembolism in Patients With Chronic Kidney Disease. , 2016, Journal of the American College of Cardiology.

[16]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[17]  J. Piccini,et al.  Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. , 2016, Journal of the American College of Cardiology.

[18]  Christopher X. Wong,et al.  Meta-Analysis of Anticoagulation Use, Stroke, Thromboembolism, Bleeding, and Mortality in Patients With Atrial Fibrillation on Dialysis. , 2016, The American journal of cardiology.

[19]  P. Schulman,et al.  Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. , 2016, Chest.

[20]  N. Obel,et al.  Long-term prognosis and causes of death after spondylodiscitis: A Danish nationwide cohort study , 2016, Infectious diseases.

[21]  D. Tarng,et al.  Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort , 2016, Circulation.

[22]  A. Camm,et al.  Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[23]  E. Edelman,et al.  Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis , 2015, Circulation.

[24]  T. Furukawa,et al.  Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. , 2014, The Cochrane database of systematic reviews.

[25]  J. Tu,et al.  Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis , 2014, Circulation.

[26]  C. Murray,et al.  Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study , 2014, Circulation.

[27]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[28]  G. Lip,et al.  Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  R. Kim,et al.  Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. , 2013, The Canadian journal of cardiology.

[30]  G. Breithardt,et al.  Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial FibrillationClinical Perspective , 2013 .

[31]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[32]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[33]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[34]  P. Kerr,et al.  Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. , 2010, Kidney international.

[35]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[36]  M. Liani,et al.  Role of Platelet Surface Receptor Abnormalities in the Bleeding and Thrombotic Diathesis of Uremic Patients on Hemodialysis and Peritoneal Dialysis , 2001, The International journal of artificial organs.